Collegium Pharmaceutical Inc
NASDAQ:COLL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.5
41.86
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Collegium Pharmaceutical Inc
Wall Street
Price Targets
COLL Price Targets Summary
Collegium Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
COLL
is 43.1 USD
with a low forecast of 37.37 USD and a high forecast of 52.5 USD.
COLL Last Price Targets
Collegium Pharmaceutical Inc
The latest public price target was made on Nov 11, 2024 by
Glen Santangelo
from
Jefferies
,
who expects
COLL
stock to
rise by 28%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Glen Santangelo
Jefferies
|
40
USD
Upside 28% |
2 weeks ago
Nov 11, 2024
|
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
StreetInsider
|
|
Oren Livnat
H.C. Wainwright
|
50
USD
Upside 60% |
2 months ago
Sep 4, 2024
|
Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright
TheFly
|
David Amsellem
Piper Sandler
|
37
USD
Upside 19% |
3 months ago
Aug 9, 2024
|
Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler
StreetInsider
|
|
Oren Livnat
H.C. Wainwright
|
47
USD
Upside 51% |
3 months ago
Jul 30, 2024
|
H.C. Wainwright Upgrades Collegium Pharmaceutical (COLL) to Buy
StreetInsider
|
|
Glen Santangelo
Jefferies
|
44
USD
Upside 41% |
5 months ago
Jun 7, 2024
|
Jefferies Upgrades Collegium Pharmaceutical (COLL) to Buy
StreetInsider
|
|
David Amsellem
Piper Sandler
|
39
USD
Upside 25% |
6 months ago
May 10, 2024
|
Piper Sandler Downgrades Collegium Pharmaceutical (COLL) to Neutral on Valuation
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is COLL's stock price target?
Price Target
43.1
USD
According to Wall Street analysts, the average 1-year price target for
COLL
is 43.1 USD
with a low forecast of 37.37 USD and a high forecast of 52.5 USD.
What is Collegium Pharmaceutical Inc's Revenue forecast?
Projected CAGR
11%
The
compound annual growth rate
of Collegium Pharmaceutical Inc's revenue for the next 3 years is
11%.
What is Collegium Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
11%
The
compound annual growth rate
of Collegium Pharmaceutical Inc's operating income for the next 3 years is
11%.
What is Collegium Pharmaceutical Inc's Net Income forecast?
Projected CAGR
70%
The
compound annual growth rate
of Collegium Pharmaceutical Inc's net income for the next 3 years is
70%.
You don't have any saved screeners yet
